Tenon Medical Expects 2025 Revenue of $3.91 Million
Tenon Medical issued a letter to shareholders from Steve Foster, President and CEO, which read in part, "2025 was marked by strong commercial execution as we advanced innovation and expanded our differentiated solutions in the marketplace. We delivered both sequential and year over year revenue growth and strengthened our liquidity position, placing Tenon on firmer financial footing heading into 2026. Our expanding product portfolio-driven by the acquisition of sacroiliac joint-specific assets from SiVantage and the recent FDA clearance and commercialization of the SImmetry+ SI Joint Fusion System-positions us to scale revenue and address a broader range of sacro-pelvic fixation and fusion needs. Entering 2026, we have laid a strong foundation for sustained growth through portfolio diversification, commercial expansion, and improved operational alignment. Following record revenue growth in the third quarter, the Company is reporting preliminary, unaudited fourth quarter revenue of approximately $1.45 to $1.48M for the period ended December 31, 2025, representing approximately 90% growth compared to the fourth quarter ended December 31, 2024. Preliminary unaudited full year 2025 revenue is expected to be approximately $3.91 to $3.94M, representing approximately 20% year over year growth. Revenue acceleration in the second half of 2025 was driven by strong procedural volume momentum, which we expect to continue into 2026. This momentum was primarily fueled by adoption among new physician users of both the Catamaran and SImmetry+ systems. These revenue results are preliminary and subject to adjustment upon completion of customary year-end audit procedures. The Company expects to report fourth-quarter and full-year 2025 financial results in March 2026...We believe 2026 will be a milestone year for Tenon, supported by a multi-platform sacro-pelvic fusion strategy that meaningfully strengthens our competitive position and enables physicians to tailor treatment to individual patient anatomy and pathology. This differentiated approach enhances our ability to drive adoption, increase procedure volumes, and capture a greater share of a rapidly expanding market, supporting long-term value creation for our shareholders. Looking ahead, we remain focused on accelerating adoption across our expanded product portfolio and leveraging recent regulatory and clinical milestones to support continued commercial growth. With a strong foundation in place, we are confident in our ability to scale operations, deepen market penetration, and deliver sustained value to our shareholders in the years ahead."
Trade with 70% Backtested Accuracy
Analyst Views on TNON
About TNON
About the author
Tenon Medical Q4 Earnings Exceed Expectations
- Earnings Highlights: Tenon Medical reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.07, indicating a positive trend in the company's profitability improvement.
- Revenue Surge: The company achieved $1.5 million in revenue for Q4, representing an 87.5% year-over-year increase, which not only reflects strong market demand recovery but also highlights the company's success in product sales and market expansion.
- Outperformance: Revenue exceeded market expectations by $120,000, demonstrating Tenon Medical's strong adaptability and growth potential in the competitive medical device industry.
- Future Outlook: With ongoing optimization of its product line and market strategies, the company is expected to further drive revenue growth and improve profitability, thereby enhancing investor confidence.
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
Tenon Medical (TNON) Q4 2025 Earnings Transcript
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
WALLACHBETH CAPITAL COMPLETES PRIVATE PLACEMENT OF SENIOR ORIGINAL ISSUE DISCOUNT CONVERTIBLE NOTES FOR TENON MEDICAL, INC, RAISING $4.3 MILLION IN GROSS PROCEEDS
Announcement of Closing: WallachBeth Capital has announced the closing of a private placement for senior original issue discount convertible notes.
Financial Details: The offering raised gross proceeds of $4.3 million.
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
Tenon Medical Q4 Earnings Exceed Expectations
- Earnings Highlights: Tenon Medical reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.07, indicating a positive trend in the company's profitability improvement.
- Revenue Surge: The company achieved $1.5 million in revenue for Q4, representing an 87.5% year-over-year increase, which not only reflects strong market demand recovery but also highlights the company's success in product sales and market expansion.
- Outperformance: Revenue exceeded market expectations by $120,000, demonstrating Tenon Medical's strong adaptability and growth potential in the competitive medical device industry.
- Future Outlook: With ongoing optimization of its product line and market strategies, the company is expected to further drive revenue growth and improve profitability, thereby enhancing investor confidence.
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
Tenon Medical (TNON) Q4 2025 Earnings Transcript
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
WALLACHBETH CAPITAL COMPLETES PRIVATE PLACEMENT OF SENIOR ORIGINAL ISSUE DISCOUNT CONVERTIBLE NOTES FOR TENON MEDICAL, INC, RAISING $4.3 MILLION IN GROSS PROCEEDS
Announcement of Closing: WallachBeth Capital has announced the closing of a private placement for senior original issue discount convertible notes.
Financial Details: The offering raised gross proceeds of $4.3 million.
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
